NASDAQ:EARSAuris Medical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Auris Medical Holding Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.03 +0.01 (+0.98 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$0.98Now: $1.03▼$1.0450-Day Range$0.78MA: $0.94▼$1.1052-Week Range$0.65Now: $1.03▼$3.20Volume146,197 shsAverage Volume370,296 shsMarket Capitalization$4.75 millionP/E RatioN/ADividend YieldN/ABeta0.17 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Auris Medical. Previous Next 2.5 Community Rank Outperform VotesAuris Medical has received 411 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAuris Medical has received 397 “underperform” votes. (Add your “underperform” vote.)Community SentimentAuris Medical has received 50.87% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote “Outperform” if you believe EARS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAuris Medical does not currently pay a dividend.Dividend GrowthAuris Medical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Auris Medical insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 2.57% of the stock of Auris Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Auris Medical are expected to decrease in the coming year, from ($2.55) to ($4.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Auris Medical is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Auris Medical is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAuris Medical has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EARS Previous Symbol CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone441-295-5950Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.70Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees9 Outstanding Shares4,610,000Market Cap$4.75 million Next Earnings Date7/16/2020 (Estimated) OptionableNot Optionable NASDAQ:EARS Rates by TradingView Receive EARS News and Ratings via Email Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter. Auris Medical (NASDAQ:EARS) Frequently Asked Questions How has Auris Medical's stock been impacted by COVID-19 (Coronavirus)? Auris Medical's stock was trading at $0.8829 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EARS stock has increased by 16.7% and is now trading at $1.03. View which stocks have been most impacted by Coronavirus. When is Auris Medical's next earnings date? Auris Medical is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Auris Medical. How were Auris Medical's earnings last quarter? Auris Medical Holding Ltd (NASDAQ:EARS) released its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60. View Auris Medical's earnings history. When did Auris Medical's stock split? How did Auris Medical's stock split work? Shares of Auris Medical reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split. Has Auris Medical been receiving favorable news coverage? Press coverage about EARS stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Auris Medical earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near future. View the latest news aboutAuris Medical. Who are some of Auris Medical's key competitors? Some companies that are related to Auris Medical include PDS Biotechnology (PDSB), Provectus Biopharmaceuticals (PVCT), Ceapro (CRPOF), Novus Therapeutics (NVUS), Adial Pharmaceuticals (ADIL), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Tetraphase Pharmaceuticals (TTPH), Unum Therapeutics (UMRX), Mateon Therapeutics (MATN), Integrated BioPharma (INBP), Intec Pharma (NTEC), Salarius Pharmaceuticals (SLRX), GT Biopharma (GTBP), Regulus Therapeutics (RGLS) and Novelion Therapeutics (NVLNF). View all competitors. What other stocks do shareholders of Auris Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXC), Anavex Life Sciences (AVXL), Flexion Therapeutics (FLXN), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Iconix Brand Group (ICON), Opko Health (OPK), RXi Pharmaceuticals (RXII) and Sophiris Bio (SPHS). Who are Auris Medical's key executives? Auris Medical's management team includes the following people: Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)Colleen A. DeVries, SVP of Cogency Global Inc. What is Auris Medical's stock symbol? Auris Medical trades on the NASDAQ under the ticker symbol "EARS." Who are Auris Medical's major shareholders? Auris Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.94%). Which major investors are selling Auris Medical stock? EARS stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. How do I buy shares of Auris Medical? Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Auris Medical's stock price today? One share of EARS stock can currently be purchased for approximately $1.03. How big of a company is Auris Medical? Auris Medical has a market capitalization of $4.75 million. The biotechnology company earns $-6,680,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Auris Medical employs 9 workers across the globe. What is Auris Medical's official website? The official website for Auris Medical is www.aurismedical.com. How can I contact Auris Medical? Auris Medical's mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The biotechnology company can be reached via phone at 441-295-5950 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
